E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
In this study we want to evaluate the role of additional topical Oxybuprocainhydrochlorid (Novain 0.4%) versus Placebo lubrication eye drops (Oculotect®) for perioperative analgesia in pediatric surgery with regard to intra- and postoperative pain management. |
|
E.2.2 | Secondary objectives of the trial |
• Anesthesia variables Durations Hemodynamic monitoring Oxygenation Intraoperative pain score Postoperative pain assessment
• Ophthalmologic variables Surgical variables Intra- and postoperative complications Functional and morphologic results
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Written informed consent to participate in the study by the parental guardian • Zero to three years of age • Uni- and bilateral cataract • Strabismus convergens or divergens • Scheduled for ophthalmic surgery
|
|
E.4 | Principal exclusion criteria |
• History of secondary cataract (inflammatory, uveitic) • History of connatal cataract associated with Rieger syndrome, Rieger-Axenfeld syndrome, Peters anomaly • History of ectoia lentis associated with Marfan syndrome, homocystinuria or Ehlers-Danlos syndrom • History of penetrating or perforating eye trauma • Previous surgery due to glaucoma, retinal detachment • Active intraocular inflammation (grade trace or above) in the study eye, like infectious conjunctivitis, scleritis, endophthalmitis as well as idiopathic or autoimmune-associated uveitis
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Amount of intraoperative analgesia with intravenous fentanyl (1 µg/kg; 0.2 mL/kg of 5 µg/kg) and the postoperative analgesia |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
• Anesthesia variables o Durations: total anesthesia time, time for intubation and extubation, time at the recovery room o Hemodynamic monitoring: heart rate, pulse, blood pressure (systolic and diastolic) o Oxygenation: intraoperative and postoperative in the recovery room o Intraoperative pain score: salivation, tearing, Bell phenomenon o Postoperative: nausea, vomiting, headache, sore throat; time to drink; time to eat; discharge same/next day
• Ophthalmologic variables o Surgical variables: duration of surgery, type of surgery o Safety o Intraoperative complications: Iris bleeding, iris prolapse, hypotony, expulsive bleeding, posterior capsule rupture, vitreous loss, globe perforation o Postoperative complications: Retinal detachment, endophthalmitis, visual axis obscuration (VAO), nystagmus, strabismus, amblyopia o Functional and morphologic results
• Demographic information o Age, gender
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
surgery day and postoperative follow-up visits: one day, one week, one, three and six months after surgery |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The trial ends one year after the initial treatment for the last enrolled patient. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |